Olema Pharmaceuticals will present OPERA-02 trial findings for breast cancer at SABCS 2025 in December.
Quiver AI Summary
Olema Pharmaceuticals, a clinical-stage biopharmaceutical company focused on targeted therapies for breast cancer, announced it will present a trial-in-progress poster for its Phase 3 OPERA-02 trial at the San Antonio Breast Cancer Symposium on December 12, 2025. The study evaluates combinations of palazestrant, an orally available complete estrogen receptor antagonist and selective estrogen receptor degrader, with ribociclib for treating frontline estrogen receptor-positive, HER2-negative advanced breast cancer. Olema's lead product, palazestrant, has shown promise in early clinical studies and has received FDA Fast Track designation for specific breast cancer indications. The company is headquartered in San Francisco and is advancing several novel therapies through its pipeline.
Potential Positives
- Olema Pharmaceuticals will present a trial-in-progress poster for the significant Phase 3 OPERA-02 trial at a prominent conference, the San Antonio Breast Cancer Symposium, which could increase visibility and interest in their clinical research.
- The OPERA-02 trial is investigating the novel treatment of palazestrant in combination with ribociclib for a specific type of advanced breast cancer, showcasing Olema's commitment to advancing targeted therapies.
- Palazestrant has received FDA Fast Track designation, indicating its potential as an important treatment for patients with ER+/HER2- metastatic breast cancer, which may facilitate faster development and approval processes.
Potential Negatives
- The announcement primarily highlights a trial-in-progress without providing specific interim results or key findings, which may raise concerns about the efficacy of palazestrant compared to existing treatments.
- The company's reliance on a single product candidate, palazestrant, for its lead position could be seen as a potential risk if the trial outcomes are not favorable.
- As a clinical-stage biopharmaceutical company, the long timeline and uncertainty associated with trial results may impact investor confidence and stock performance.
FAQ
What is the OPERA-02 trial about?
The OPERA-02 trial evaluates palazestrant combined with ribociclib for treating advanced ER+/HER2- breast cancer.
When will the OPERA-02 trial poster be presented?
The poster will be presented on December 12, 2025, at the SABCS 2025 symposium.
What is palazestrant (OP-1250)?
Palazestrant is an orally available therapy acting as a complete estrogen receptor antagonist and a selective estrogen receptor degrader.
How does palazestrant work?
Palazestrant blocks estrogen receptor activity in metastatic ER+ breast cancer and shows promising anti-tumor efficacy.
What designation has palazestrant received from the FDA?
Palazestrant has been granted Fast Track designation for treating metastatic ER+/HER2- breast cancer post-endocrine therapy.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$OLMA Insider Trading Activity
$OLMA insiders have traded $OLMA stock on the open market 4 times in the past 6 months. Of those trades, 0 have been purchases and 4 have been sales.
Here’s a breakdown of recent trading of $OLMA stock by insiders over the last 6 months:
- CYRUS HARMON has made 0 purchases and 4 sales selling 25,000 shares for an estimated $204,840.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$OLMA Hedge Fund Activity
We have seen 71 institutional investors add shares of $OLMA stock to their portfolio, and 56 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- JANUS HENDERSON GROUP PLC added 3,022,784 shares (+inf%) to their portfolio in Q2 2025, for an estimated $12,877,059
- WOODLINE PARTNERS LP added 2,027,986 shares (+137.2%) to their portfolio in Q2 2025, for an estimated $8,639,220
- POINT72 ASSET MANAGEMENT, L.P. removed 1,441,690 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $6,141,599
- WELLINGTON MANAGEMENT GROUP LLP removed 1,245,658 shares (-84.5%) from their portfolio in Q2 2025, for an estimated $5,306,503
- MORGAN STANLEY added 985,716 shares (+218.2%) to their portfolio in Q2 2025, for an estimated $4,199,150
- BLACKROCK, INC. added 782,767 shares (+20.5%) to their portfolio in Q2 2025, for an estimated $3,334,587
- AMERIPRISE FINANCIAL INC added 773,064 shares (+193.4%) to their portfolio in Q2 2025, for an estimated $3,293,252
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$OLMA Analyst Ratings
Wall Street analysts have issued reports on $OLMA in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Guggenheim issued a "Buy" rating on 10/08/2025
- Oppenheimer issued a "Outperform" rating on 09/03/2025
- Citigroup issued a "Buy" rating on 08/12/2025
- Goldman Sachs issued a "Buy" rating on 05/14/2025
To track analyst ratings and price targets for $OLMA, check out Quiver Quantitative's $OLMA forecast page.
$OLMA Price Targets
Multiple analysts have issued price targets for $OLMA recently. We have seen 6 analysts offer price targets for $OLMA in the last 6 months, with a median target of $21.5.
Here are some recent targets:
- Emily Bodnar from HC Wainwright & Co. set a target price of $28.0 on 10/20/2025
- Brad Canino from Guggenheim set a target price of $20.0 on 10/08/2025
- Matthew Biegler from Oppenheimer set a target price of $22.0 on 09/03/2025
- Anupam Rama from JP Morgan set a target price of $29.0 on 08/14/2025
- Yigal Nochomovitz from Citigroup set a target price of $21.0 on 08/12/2025
- Richard Law from Goldman Sachs set a target price of $18.0 on 05/14/2025
Full Release
SAN FRANCISCO, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced it will present a trial-in-progress poster for the Phase 3 OPERA-02 trial at the 2025 San Antonio Breast Cancer Symposium (SABCS 2025) taking place December 9-12, 2025 in San Antonio, TX. The trial is evaluating palazestrant in combination with ribociclib in frontline estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer.
Poster Presentation Details
Title:
OPERA-02: a phase 3 randomized, double-blind, active-controlled study of palazestrant with ribociclib versus letrozole with ribociclib for the first-line treatment of ER+, HER2- advanced breast cancer
Abstract Number:
264
Presentation Number:
PS5-12-18
Date/Time:
Friday, December 12, 2025 from 12:30pm–2:00pm CT / 1:30pm–3:00pm ET
Additional information can be found on the SABCS website . A copy of the poster will be made available on the Publications page of Olema’s website in alignment with the SABCS 2025 embargo policy.
About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor antagonist (CERAN) and a selective estrogen receptor degrader (SERD), currently in two Phase 3 clinical trials. In addition, Olema is developing OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor, now in a Phase 1 clinical study. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit
www.olema.com
.
About Palazestrant (OP-1250)
Palazestrant (OP-1250) is a novel, orally available small molecule with dual activity as both a complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD). It is currently being investigated in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. In clinical studies, palazestrant completely blocks ER-driven transcriptional activity in both wild-type and mutant forms of metastatic ER+ breast cancer and has demonstrated anti-tumor efficacy along with attractive pharmacokinetics and exposure, favorable tolerability, central nervous system penetration, and combinability with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors. Palazestrant has been granted U.S. Food and Drug Administration (FDA) Fast Track designation for the treatment of ER+/HER2- metastatic breast cancer that has progressed following one or more lines of endocrine therapy with at least one line given in combination with a CDK4/6 inhibitor. It is being evaluated as a single agent in the ongoing pivotal Phase 3 clinical trial, OPERA-01 and in combination with ribociclib in the ongoing pivotal Phase 3 clinical trial, OPERA-02. Palazestrant is also being evaluated in multiple Phase 1/2 studies in combination with ribociclib, palbociclib, alpelisib, everolimus, and atirmociclib.
Media and Investor Relations Contact
Courtney O’Konek
Vice President, Corporate Communications
Olema Oncology
[email protected]
